Effects of JWH-018 and Its Metabolites on Cannabinoid Receptors
Author Information
Author(s): Lisa K. Brents, Emily E. Reichard, Sarah M. Zimmerman, Jeffery H. Moran, William E. Fantegrossi, Paul L. Prather
Primary Institution: University of Arkansas for Medical Sciences
Hypothesis
The high adverse effect occurrence associated with K2 products is due, at least in part, to distinct JWH-018 metabolite activity at the cannabinoid 1 receptor (CB1R).
Conclusion
JWH-018 and its hydroxylated metabolites retain significant activity at CB1Rs, which may explain the greater prevalence of adverse effects observed with K2 products compared to cannabis.
Supporting Evidence
- JWH-018 and its metabolites showed high affinity for CB1Rs.
- The metabolites produced full agonist levels of activation at CB1Rs.
- JWH-018 and its metabolites caused significant decreases in locomotor activity and core body temperature in mice.
Takeaway
This study found that a synthetic drug called JWH-018 and its breakdown products can strongly affect brain receptors, which might make people feel worse than using regular marijuana.
Methodology
The study used competition binding assays and G-protein activation assays in mouse brain homogenates to evaluate the affinity and efficacy of JWH-018 and its metabolites at CB1Rs.
Limitations
The study primarily focused on in vitro and in vivo effects in mice, which may not fully translate to human responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website